Prognostic significance of the Systemic Immune-Inflammation Index in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) patients.

IF 3.7 4区医学 Q1 DERMATOLOGY

Clinical and Experimental Dermatology Pub Date : 2024-08-16 DOI:10.1093/ced/llae332

Winn Hui Han, Tobias Tshung En Wong, Ruhana Che Yusof, Rebecca Kai Jan Choong, Shin Shen Yong, Nik Aimee Azizah Faheem, Zhenli Kwan

{"title":"Prognostic significance of the Systemic Immune-Inflammation Index in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) patients.","authors":"Winn Hui Han, Tobias Tshung En Wong, Ruhana Che Yusof, Rebecca Kai Jan Choong, Shin Shen Yong, Nik Aimee Azizah Faheem, Zhenli Kwan","doi":"10.1093/ced/llae332","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory markers such as neutrophil-lymphocyte ratio (NLR) and eosinophil count are known prognostic indicators for SJS/TEN severity. This study explored the correlation of systemic immune-inflammatory index (SII), platelet-lymphocyte ratio (PLR) and NLR with SCORTEN and patient outcomes. A retrospective audit of 34 SJS/TEN patients (25 SJS, 3 SJS/TEN overlap, 6 TEN) was conducted from 2018 to 2022 revealed mean admission values of SII 1597 (standard deviation (SD) 1904.18), NLR 6.52 (SD 5.99) and PLR 201.74 (SD 135.01). Cut-off values for predicting mortality were SII 1238.25 (area under ROC (AUROC) 0.82), NLR 8.32 (AUROC 0.8) and PLR 284.66 (AUROC 0.78). Multiple logistic regression using a backward stepwise method identified SCORTEN as a significant factor associated with mortality (p=0.029) after adjusting for SII, NLR and PLR. None of the inflammatory markers significantly predicted mortality, although admission PLR may be a potential risk factor (p=0.053).</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llae332","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Inflammatory markers such as neutrophil-lymphocyte ratio (NLR) and eosinophil count are known prognostic indicators for SJS/TEN severity. This study explored the correlation of systemic immune-inflammatory index (SII), platelet-lymphocyte ratio (PLR) and NLR with SCORTEN and patient outcomes. A retrospective audit of 34 SJS/TEN patients (25 SJS, 3 SJS/TEN overlap, 6 TEN) was conducted from 2018 to 2022 revealed mean admission values of SII 1597 (standard deviation (SD) 1904.18), NLR 6.52 (SD 5.99) and PLR 201.74 (SD 135.01). Cut-off values for predicting mortality were SII 1238.25 (area under ROC (AUROC) 0.82), NLR 8.32 (AUROC 0.8) and PLR 284.66 (AUROC 0.78). Multiple logistic regression using a backward stepwise method identified SCORTEN as a significant factor associated with mortality (p=0.029) after adjusting for SII, NLR and PLR. None of the inflammatory markers significantly predicted mortality, although admission PLR may be a potential risk factor (p=0.053).

查看原文本刊更多论文

史蒂文-约翰逊综合征和中毒性表皮坏死溶解症（SJS/TEN）患者全身免疫炎症指数的预后意义。

中性粒细胞-淋巴细胞比值（NLR）和嗜酸性粒细胞计数等炎症标志物是SJS/TEN严重程度的已知预后指标。本研究探讨了全身免疫炎症指数（SII）、血小板-淋巴细胞比值（PLR）和 NLR 与 SCORTEN 和患者预后的相关性。2018年至2022年对34例SJS/TEN患者（25例SJS、3例SJS/TEN重叠、6例TEN）进行了回顾性审计，结果显示平均入院值为SII 1597（标准差（SD）1904.18）、NLR 6.52（SD 5.99）和PLR 201.74（SD 135.01）。预测死亡率的临界值为 SII 1238.25（ROC 下面积 (AUROC) 0.82）、NLR 8.32（AUROC 0.8）和 PLR 284.66（AUROC 0.78）。在对 SII、NLR 和 PLR 进行调整后，采用后向逐步法进行多元逻辑回归，发现 SCORTEN 是与死亡率相关的重要因素（p=0.029）。尽管入院 PLR 可能是一个潜在的风险因素（p=0.053），但没有一个炎症标志物能显著预测死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

2.40%

发文量

389

审稿时长

3-8 weeks

期刊介绍： Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.